等待开盘 05-22 09:30:00 美东时间
+0.150
+3.47%
今日重点评级关注:Chardan Capital:维持Senti Biosciences"买入"评级,目标价从11美元升至12美元;Ladenburg Thalmann:维持Usio"买入"评级,目标价从5.75美元升至6.25美元
05-18 11:48
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据AVITA Medical业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** 2026年第一季度营收1,930万美元,同比增长4%,环比增长约10%(相比2025年第四季度),为过去一年中最高季度营收。 **盈利能力:** 毛利率81.7%,净亏损1,060万美元(每股亏损0.35美元),较上年同期净亏损1,390万美元(每股亏损0.53美元)有所改善。 **现金状况:** 季度净现金消耗990万美元,期末现金及有价证券余额1,430万美元。 **成本控制:** 运营费用2,450万美元,同比下降11%。 ## 2.
05-16 12:12
Lake Street analyst Frank Takkinen upgrades AVITA Medical (NASDAQ:RCEL) from Hold to Buy and raises the price target from $3.5 to $6.
05-16 01:44
AVITA Medical (NASDAQ:RCEL) released first-quarter financial results and hosted...
05-15 05:26
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective
04-30 20:52
Avita Medical names Cary Vance CEO after interim tenure Avita Medical appointed Cary Vance as president, chief executive officer, effective immediately. Vance served as interim CEO since October 2025. Board elected Jan Stern Reed as chair, effective immediately. Reed has served on board since 2021.
04-30 20:50
Agreement ensures rapid nationwide access to RECELL® for burn mass casualty incidents, providing BARDA access to 3,000 units any time over the 10-year contract VALENCIA, Calif., April 08, 2026 (GLOBE NEWSWIRE)
04-09 04:17
今日重点评级关注:韦德布什:维持TScan Therapeutics"跑赢大市"评级,目标价从4美元升至5美元;HC Wainwright & Co.:维持莱斯康制药"买入"评级,目标价从4美元升至6美元
03-06 11:58